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Prokineticins (Prok-1 and Prok-2) belong to a newly identified AVIT protein family. They are involved in variety of activities in various
tissues, including smooth muscle contraction of the gastrointestinal tract and promoting proliferation of endothelial cells derived from adrenal
gland. Importantly, they also act as the survival factors to modulate growth and survival of neurons and hematopoietic stem cells. In this study we
demonstrated that Prok-1 (but not Prok-2) protein is expressed in the mucosa and mesenchyme of the mouse embryonic gut during enteric nervous
system development. Its receptor, PK-R1 is expressed in the enteric neural crest cells (NCCs). To elucidate the physiological role(s) of Prok-1 in
NCCs, we isolated the NCCs from the mouse embryonic gut (E11.5) and cultured them in the form of neurospheres. In an in vitro NCC culture,
Prok-1 was able to activate both Akt and MAPK pathways and induce the proliferation and differentiation (but not migration) of NCCs via PK-R1.
Knock-down of PK-R1 using siRNA resulted in a complete abolishment of Prok-1 induced proliferation. Taken together, it is the first report
demonstrating that Prok-1 acts as a gut mucosa/mesenchyme-derived factor and maintains proliferation and differentiation of enteric NCCs.
© 2007 Elsevier B.V. All rights reserved.Keywords: Prokineticin-1; Neural crest cell; Proliferation; Differentiation1. Introduction
The enteric nervous system (ENS) in mammals is derived
from the neural crest cells (NCC) which enter the foregut and
colonize the entire wall of gastrointestinal tract [1]. Failure to
completely colonize the gut results in the absence of enteric
ganglia, as seen in Hirschsprung's (HSCR) disease in humans.
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doi:10.1016/j.bbamcr.2007.01.013opment is mediated by a combination of mechanism, involving
both regional environmental factors as well as cell-intrinsic
mediators encoded in NCCs. Glial-derived neurotrophic factor
(GDNF) and its receptor, Ret, are the most critical players in
ENS development [2,3]. Coding region mutations in RET
account for approximately 50% of familial HSCR cases [4]
and mice with null mutations in either Ret (Ret k−) or Gdnf
(Gdnf −) have complete intestinal aganglionosis [5–10]. Other
factors, such as endothelin 3 (EDN3) and its receptor
(EDNRB) [11]; sonic hedgehog (Shh) and its receptor (Ptc)
[12]; Sox 10 [13]; Phox2b [14], Mash-1 [15] are also known to
be crucial for ENS development. However, coding region
mutations in the HSCR genes identified so far cannot account
for all HSCR patients. Incomplete penetrance of the mutations
and variable expression of the phenotype indicate that
additional genes may be implicated in the disease. This has
led to the search for other susceptibility genes that could lead
to HSCR.
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to as endocrine gland derived vascular endothelial growth
factor (EG-VEGF) and Bv8, respectively [16,17]. They belong
to a newly- identified family of secreted proteins, the AVIT
protein family [18]. These proteins were first identified in the
gastrointestinal tract as potent agents mediating muscle
contraction [17]. More recently, they have been found to be
widely distributed in mammalian tissues. Prok-1 mRNA
expression has been described in a variety of tissues, in
steroidogenic glands such as the ovary, testis, adrenal gland
and placenta [19–23], and also in the brain, colon, skeletal
muscle, small intestine, spleen, thymus liver, bladder, prostate
and uterus [19,24,25]. Prok-2, on the other hand, is most
highly expressed in testis, colon, brain and peripheral blood
leukocytes [16,26,27].
These two prokineticins bind not only to PK-R1, but also the
other closely related G protein-coupled receptor, PK-R2.
Receptor activation leads to mobilization of calcium, stimula-
tion of phosphoinositide turnover, and activation of p44/p42
MAPK signaling pathways [28]. It is currently known that
prokineticins possess diverse biological functions. Besides
promoting the contraction of gastrointestinal smooth muscle,
they also promote angiogenesis in ovary [23,29] and testis [26];
induce proliferation, migration and fenestration of endothelial
cells derived from adrenal gland [17]; support neuronal survival
[30]; cause hyperalgesia of skin; and control pain sensation [31]
and behavioral circadian rhythms [18]. These two receptors
have also been found recently in human and mouse hemato-
poietic stem cells and specific mature blood cells, including
lymphocytes. Prokineticins can modulate growth, survival, and
function of cells of the innate and adaptive immune systems,
possibly through autocrine or paracrine signaling mechanisms
[27]. Given the reported expression patterns and activities of the
mammalian orthologs in the brain [16,30], reproductive tract
[19,23,24,32], and cells of the immune system [27], the
molecules seem to have subserved similar functions across
evolution. Besides being angiogenic factors, prokineticins seem
to be universal survival/mitogenic factors for various cells
including endothelial cells, neuronal cells, lymphocytes and
hematopoietic stem cells.
Interestingly, prokineticins and their receptors have been
detected in mouse embryos as early as at E7, though their roles
during embryonic development remain unclear. In this report
we provide evidence that Prok-1 is involved in ENS
development. First, we demonstrated that Prok-1 protein is
expressed in the mucosa and mesenchyme of the mouse
embryonic gut during ENS development (E11.5–E15.5).
Secondly, its receptor PK-R1 (but not PK-R2) was shown to
be present in enteric neural crest cells (NCCs). More
importantly, functional studies using NCC culture demonstrated
that Prok-1 activates Akt and MAPK pathways and induces the
proliferation and differentiation of NCCs. The receptor PK-R1
activation was critical for Prok-1 induced proliferation and was
completely abolished by knocking down PK-R1 using siRNA.
Taken together, these findings provide evidence that Prok-1 is a
new modulator for the proliferation and differentiation of
enteric NCCs.2. Methods and materials
2.1. Animals
For cultures of enteric NCCs, wild-type ICR mice were used. The day of a
vaginal plug observed was considered E0.5.
2.2. Immunohistochemistry
Immunohistochemical study was performed on mouse embryos at different
embryonic stages (E11.5–E17.5). Mouse embryonic samples were fixed and
embedded in paraffin, subsequently sectioned and mounted on glass slides.
Rabbit polyclonal antiserum to hProk-1 (1:200) was generated against a
synthetic peptide of the C- terminus of hProk-1 (residues 87–105) (Zymed, San
Francisco, CA) as described (27); hPK-R1 (1:150); hPK-R2 (1:150) (Lifespan
Biosciences, Inc, Seattle, WA) were used for immunohistochemistry. For
histological analysis, paraffin sections of mouse embryos were rehydrated using
standard protocols and microwaved for 10 min in 10 mM sodium citrate pH 6.0.
Sections were then incubated with the antibodies followed by incubation with
secondary antibodies, anti-rabbit-IgG-Texas Red (1:200, Molecular Probe,
Eugene, OR) and anti-mouse-IgG-FITC (1:200, Calbiochem, San Diego, CA)
and mounted with aqueous mounting media (Vector, Burlingame, CA).
2.3. In situ hybridization
The Prok-1 and PK-R1 containing plasmids [24] were linearized with the
appropriate restriction enzymes. The DIG-labelled antisense and sense
transcripts were generated using T3 and T7 RNA polymerase separately with
DIG RNA labeling kit (Roche, Basel Switzerland). Slides were dewaxed,
rehydrated, and hybridized overnight in a humid box (containing 50%
formamide, 5× SSC) with a sense or antisense DIG-labelled probe in
hybridization solution (50% deionized formamide, 0.3 M NaCl, 5 mM EDTA,
20 mM Tris–HCl, 10% dextran sulphate, 2× Denhardt's buffer, 0.5 mg/ml yeast
tRNA, 10 mM DTT) at 60 °C. Following a series of washings under stringent
conditions (2× SSC/50% formamide and 0.1× SSC/30% formamide at 60 °C),
the hybridization signal was amplified with Tyramide Signal Amplification
system and Streptavidin-FITC conjugate in accordance with the manufacturer's
protocol (TSA Biotin System; PerkinElmer, Wellesley, MA). The sections were
then stained with the secondary antibody conjugated with Texas Red (anti-
rabbit-IgG-Texas Red, 1:200, Molecular Probe). Finally, sections were counter-
stained with DAPI and mounted with aqueous mounting media (Vector).
2.4. Neurosphere culture
E11.5 ICR mouse guts (from stomach to hindgut) were dissected in L15
medium (Invitrogen, Rockville, MD). Guts were washed with Ca2+ and Mg2+
free PBS and digested with collagenase/dispase (0.2 μg/ml each; 37 °C for
10 min). Digested guts were triturated into single cells and filtered through cell
strainers (100 μm and then 40 μm), washed with L15, resuspended in NCC
medium, DMEM containing 15% Chick embryo extract (SIL, Sussex, UK),
FGF (20 ng/ml, Sigma, St. Louis, MO), EGF (20 ng/ml, Sigma), Retinoic acid
(35 ng/ml, Sigma), N2 (1%), B27 (2%, Invitrogen), β-mercaptoethanol
(50 mM, Sigma), and plated onto poly-D-lysine- and fibronectin (20 μg/ml
each, Life Technologies Inc.)-coated wells according to a previously-described
protocol [12]. Mesenchyme cells grow as a monolayer, and NCCs form clusters.
Cultures were replated (8×104 cells per each 35-mm wells) once every 3–
5 days, and very few mesenchyme cells remained in culture after three passages.
2.5. Immunofluorescence
Immunofluorescence analyses were performed to localize NCCs and their
derivatives using antibodies that recognized antigens of NCCs, neurons, glia,
myofibroblast, proliferative cells, and apoptotic cells in accordance with a
previously-described protocol [12]. Immunocytochemical analysis for NCCs
was performed either using coated slides and the cytospin system (Thermo
Shandon, Pittsbrugh, PA) or cells plated on chamber slides (Nalge Nunc). NCCs
were fixed and blocked, were then incubated with primary antibodies: Ret (1:50,
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protein, GFAP (1:200, DAKO, Copenhagen, Denmark); Neurofilament M
(1:500, Chemicon); Smooth muscle actin, SMA (1:400, DAKO); Tyrosine
hydroxylase, TH (1:200, Chemicon); S100β (1:1000, Sigma) and nNOS (1:200,
Cell signaling Tech., Beverly, MA, USA). The secondary antibodies used were
Texas Red conjugated anti-rabbit (1:200) and FITC conjugated anti-mouse
(1:200) from Molecular Probes and Zymed, respectively. Ret expressing cells
were visualized with Tyramide Signal Amplification system and Streptavidin-
Texas Red conjugate, in accordance with the manufacturer's protocol (TSA
Biotin System).
2.6. BrdU incorporation and immunocytochemistry
BrdU incorporation was performed using In situ Cell Proliferation kit Fluos
(Roche, Indianapolis, IN). The cells were treatedwith recombinantmouse Prok-1
(ED50 is 2–4 μg/ml, R&D,Minneapolis,MN)with concentrations of 2–4 μg/ml,
recombinant human GDNF (50 ng/ml, PeproTech, Rocky Hill, NJ) or in
combination for 24 h. BrdU was added 16 h before the termination of culture.
Culture was fixed, blocked and incubated with anti-Ret antibody (1:50) (IBL).
The immunosignal was amplified with Tyramide Signal Amplification system
and Streptavidin- Texas Red conjugate. Genomic DNAwas denatured in 4N HCl
(5 min at RT). After PBS washing, the cultures were incubated with fluorescein-
conjugated anti-BrdU antibody (Roche). Slides were washed in PBS and
mounted with aqueous mounting media.
2.7. Cell proliferation assay
NCCs (Passage 4) were seeded at 1×104 cells /well in 96-well culture plates
in NCC medium 20 h before treatment. The cells were treated with recombinant
mouse Prok-1 with concentrations of 2–4 μg/ml in triplicate for 24 h in presence
or absence of the PI-3-K inhibitor (10 μM, LY294002) and MAPK inhibitor
(20 μM, PD98059) (Calbiochem), respectively. BrdU (1:1000) was added into
culture 16 h before the assay. The culture was fixed, blocked, and incubated with
anti-BrdU antibody. The cell proliferation rate was measured using Cell
Proliferation ELISA kit, colorimetric (Roche). Three independent experiments
were preformed and each in triplicate.
2.8. TUNEL
Apoptotic cells in neurosphere were analyzed on cytospin preparation of
neurospheres using in situ Cell Death Detection kit, Fluorescein (Roche),
following the manufacturer's protocol.
2.9. Gut explant culture
E11.5 midguts were isolated from ICR mice and both ends of the gut were
placed on the filter membrane (0.45 μm, black gridded HABG, Millipore) as
described [12]. The explants were then cultured in DMEM supplemented with
10% FBS in the absence (vehicle) or presence of Prok-1 (4 μg/ml), GDNF
(100 ng/ml) or in combination for 48 h. Then, Tuj1+ NCCs migrated onto the
membrane were then visualized by immunostaining with anti-Tuj1 antibody.
2.10. RT-PCR
Total RNA was isolated from NCCs by TRIzol reagent (Life technologies
Inc.) and reverse transcribed in 20 μl reaction system using SuperScript™ RNA
Amplification System, in accordance with the manufacturer's instructions. PCR
reactions were performed using specific primers: PK-R1 (Forward: 5′
GCGGCATTGGAAACTTCA3′; Reverse: 5′GGCCCACGAATTCTATGCC
3′) for 35 cycles; PK-R2 (Forward: 5′CGGCAGCTCTCCTGGGAG-
CATGGC3′; Reverse: 5′CGTCTGGAACCCAGGGACTGCC3′) for 40 cycles;
NOS (Forward: 5′GATCCAGTGGTCCAAGCTGCAG3′; Reverse: 5′CAG-
CAGCATGTTGGACACAGCG3′); ChAT (Forward: 5′GACCAGC-
TAAGGTTTGCAGCCAG3′; Reverse: 5′CTCAACTGAGTGAACA-
GATCA3′); VIP (Forward: GTAGGCTGGATGACAGGATG3′; Reverse: 5′
GTAGTTATCTGTGAAGACGGC3′; NLF (Forward: 5′CCAGGTA
GCCGCCATCAGCCAG3′; Reverse:5′GCGAGCCTGCAGGTTGCG-CAGA3′) for 30 cycles; actin (Forward: 5′ GAATTCATTTTTGAGACCTT-
CAA 3′; Reverse: 5′ CCGGATCCATCTCTGCCTCGAAGTCCA 3′) for 25
cycles. The estimated sizes of RT-PCR products for PKR1, PK-R2, NOS, ChAT,
VIP, NLF and actin were 506, 432 bp, 462 bp, 314 bp, 298 bp, 320 bp and
306 bp, respectively.
2.11. Immunoblotting
To analyze levels of phosphorylation of AKT and MAPK proteins, cells
were plated at 0.2×106 cells/well in 6-well dish 2 days prior to treatment. The
attached cells were then starved in phenol-red free medium in absence of CEE
for 16 h before the treatments. The cells were then treated with Prok-1 (4 μg/ml)
in the presence or absence of PI-3-K inhibitor (LY294002, 10 μM) and MAPK
inhibitor (PD98059, 20 μM) for 24 h before harvesting. In total, 20 μg of total
protein from cell lysates was separated on 10% SDS-polyacrylamide gels and
blotted with a 1:1000 dilution of antibodies against phospho-AKT (Ser 473),
phospho-MAPK (p44/p42), total AKT, or total MAPK (p44 and p42) (Cell
Signaling). The same membranes were analyzed with a 1: 2500 dilution of anti-
β-actin monoclonal antibody (Chemicon International, Inc., Temecula, CA,
USA) as a protein loading control. All blots were incubated with 1:5000 dilution
of secondary HRP-conjugated anti-mouse or anti-rabbit antibody (Amersham
Pharmacia Biotech., Piscataway, NJ, USA).
2.12. Statistical analysis
Differences among multiple treatment groups were analyzed by one-way
analysis of variance ANOVA followed by the Tukey posttest. A p value less
than 0.05 represented a statistically-significant difference.
3. Results
3.1. Prok-1 is a mucosa/mesenchymal-derived factor in mouse
embryonic gut
In mice, NCCs reach the foregut at approximately embryonic
day 10.5 (E10.5) and complete their colonization by∼E14.5. To
substantiate the potential role(s) of these peptides in enteric
nervous system development, spatial–temporal expression
patterns of Prok-1 and Prok-2 in the guts of mouse embryos
were analyzed by immunohistochemistry and in situ hybridiza-
tion. At E11.5 upwards, NCCs coalesced into presumptive
myenteric region between developing longitudinal and circular
muscles at the outer circumference underneath the serosa as a
layer of cells and express NCC marker, p75NTR and the
neuronal precursor marker, Tuj1. Immunohistochemistry using
antibody against Prok-1 showed that Prok-1 protein is
expressed in both the mucosa and mesenchyme. At E15.5,
relatively higher expression of Prok-1 was observed in mucosa
(Fig. 1C). The primary-minus control or staining with peptide
pre-absorbed antibody (data not shown) showed a weak non-
specific signal (Fig. 1, Ctrl, D). This observation was further
confirmed by localizing Prok 1 transcripts detected in mucosa/
mesenchyme region using in situ hybridization (Fig. 1E–G).
Prok-1 expression was not detected in the enteric ganglia at the
stages examined (Fig. 1). On the contrary, the structurally
related family member Prok-2 was not detected in the
embryonic guts by in situ hybridization (data not shown).
3.2. PK-R1, but not PK-R2, is expressed in enteric NCCs
The existence of receptors is required for Prok-1 to exert its
function(s), so the expressions of the receptors of prokineticins,
Fig. 1. Spatial and temporal expression of Prok-1 in mouse embryonic guts. (A–C) Immunohistochemistry using antibody specific to Prok-1. Prok-1 protein was
localized at the mucosa and mesenchyme of the embryonic guts (E11.5–15.5) (Red). (D) The immunosignals were specific because no signal was detected in the
primary-minus control (Ctrl). NCCs were localized at the gut mesenchyme using anti-Tuj1 antibody (Green). (E–H) In situ hybridization analysis of Prok-1 expression
in mouse embryonic guts (E11.5–15.5, E–G) using DIG-labeled antisense and sense (Ctrl, H) probes. Consistently, Prok-1 transcripts were located in both the mucosa
and mesenchyme. Signal was specific because no signal was detected when sense probe was used (Ctrl, H). Bars 100 μm.
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using PK-R1 specific antibody showed that PK-R1 protein is
localized in both the gut mesenchyme and presumptive
myenteric region underneath the serosa (Fig. 2). Tuj1 and PK-R1 double-staining in enteric NCCs confirms that PK-R1 is
expressed by enteric neurons (Fig. 2C, G). The signal was
specific because only weak signal was seen in the mucosa
region when IgG isotype control was used (Fig. 2D). Expression
Fig. 2. Localization of PK-R1 in mouse embryonic guts. Representative figures from immunohistochemical analysis using antibody specific to PK-R1 on mouse
embryonic gut (A–C: E11.5 and E–G: E13.5). NCCs were located at the gut mesenchyme with Tuj1 antibody (A and E, green). Immunosignal specific to PK-R1
protein was detected at both NCCs and mesenchyme of guts (B and F). (D) Staining with IgG isotype control showed a weak nonspecific signal. Photos A–C and E–G
were taken at the same magnification (400×). Photos D were taken at 200×. Bars 100 μm.
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hybridization and using another NCC marker, p75NTR+ (data
not shown). Noteworthy, although PK-R1 was found in the
embryonic gut, PK-R2 was not (data not shown).
3.3. Prok-1 promotes proliferation of NCCs
In an attempt to further demonstrate that PK-R1 is expressed
in “primitive” NCCs, we isolated the NCCs from E11.5
embryonic guts and enriched in culture as described [12] for
this study. The isolated NCCs are “primitive” (p75NTR+/Ret+/
Tuj1−) and expressed various transcription factor genes
characteristic of embryonic NCCs, including slug, snail, twist,
Pax3 and Sox10 (data not shown). Using semi-quantitative RT-
PCR, we confirmed the expression of PK-R1 in NCCs, wherehuman endometrium was used as positive control (Fig. 3A). To
assess the mitogenic potential of Prok-1 on NCCs, BrdU
incorporation assays were performed in the absence or presence
of Prok-1. Based on the information provided by the supplier
(R&D), the ED50 of the recombinant mouse EG-VEGF (Prok-
1) is 1–4 μg/ml (85 nM–340 nM), which is determined by its
ability to stimulate 3H-thymidine incorporation by EJG cells
(endothelial cell line derived from adrenal tissue). Therefore,
the concentration we used in the experiments is the ED50 of this
recombinant peptide recommended by the product provider (2
and 4 μg/ml). After 24-h treatments with vehicle (Ctrl) and
Prok-1, NCCs were stained with NCC marker (Ret) and BrdU
antibodies. Consistently, 26.6±2.7% of NCCs were proliferat-
ing (Ret+/BrdU+) in vehicle control, whereas Prok-1 increased
proliferating cells (Ret+/BrdU+) to 43.5±3.7% (p<0.05) (Fig.
Fig. 3. Prok-1 promotes the proliferation of NCCs. (A) PK-1, but not Prok-1 or PK-R2, transcript was detected in isolated NCCs by RT-PCR. cDNA of human
endometrium were used as the positive control. Actin was used as the internal control. (B) BrdU incorporation and immunocytochemistry. NCCs were cultured in the
absence (Vehicle) or presence of Prok-1 for 24 h. NCCs were then stained with anti-Ret antibody (Red) and proliferative cells were detected with anti-BrdU antibody
(Green). Pictures at upper panel and lower panel were taken at 200× and 400×, respectively. Bars 100 μm. The percentages of proliferating NCCs (Ret+/BrdU+) in
Vehicle control and Prok-1 treated culture were summarized in the table below. (At least three randomly chosen fields of total 200 cells from each culture were counted)
(C) Cell proliferation ELISA assay. NCCs were treated with vehicle, increasing concentration Prok-1 for 24 h. Proliferating cells had been incorporated with BrdU;
then the relative proliferation rate was measured by ELISA using anti-BrdU antibody. (D) RT-PCR analysis on the expression of PK-R1 in NCCs 24 h after transfection
with PK-R1 siRNA and the non-silencing control (Ctrl). Cell proliferation ELISA assays were performed in siRNA transfected NCCs treated with or without Prok-1.
The value reported in bar charts represent the mean±SEM of 3 independent assays, each in triplicate. Data were analyzed by one-way ANOVA followed by the Tukey
posttest. A p value less than 0.05 is representing statistical significance.
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ELISA assay was used, a dose dependent increment (2 μg/ml:
12.5±2.4% 4 μg/ml: 23.7±2.8% p<0.05) on the proliferation
rate was observed with Prok-1 treatment, relative to the vehicle
treated control (Fig. 3C). TUNEL assays were also performed to
examine the apoptotic cells in the culture and only a very small
proportion of apoptotic cells were found in the culture either in
the presence or the absence of Prok-1 (data not shown).To directly evaluate whether PK-R1 is crucial for Prok-1
mediated proliferation, we transfected PK-R1 siRNA or a
control siRNA into the NCCs and cultured for 24 h after Prok-1
stimulation. According to RT-PCR analysis, PK-R1 expression
decreased significantly in cells transfected with PK-R1 siRNA
when compared to that of the cells transfected with the control
siRNA (Fig. 3D). Consistently, PK-R1 knockdown completely
abolished Prok-1 induced proliferation (Fig. 3D).
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NCCs
Besides promoting proliferation, Prokineticins have also
been shown to be able to stimulate the differentiation of
hematopoietic cells [27]. To further assess the ability of Prok-1
to induce differentiation of NCCs, Prok-1 was administrated to
NCC culture for 48 h. Like GDNF, Prok-1 induced the
expression of neuron- (Tuj1+/TH+/NFL+) and glial- (GFAP+/Fig. 4. Prok-1 promotes differentiation but not migration of NCCs. (A) Prok-1 induce
immunocytochemical analysis of Prok-1 treated NCCs. NCCs were cultured in the pre
slides and subjected to immunocytochemical analysis using antibodies specific to neu
vehicle control, majority of cells remained “primitive” and express neither neuronal no
NCCs were found in the culture containing Prok-1. The percentages of cells express
table. At least three randomly chosen fields of total 200 cells from each culture were c
(B) Immunocytochemical analysis of Prok-1 treated NCCs with nNOS antibody. NC
Pictures were taken at 200×. Bars 100 μm. (C) Expression of neurofilament L (NFL),
(NOS) in Prok-1 treated NCCs (6 days) were analyzed by RT-PCR. Actin was used as
on the filter membrane. The explants were then cultured in the absence (vehicle) or pr
the membrane were then visualized by immunostaining with anti-Tuj1 antibody. BaS100+) specific markers (Fig. 4A). In addition, the long-term
treatment with Prok-1 (6 days) also up-regulated the expression
of neuronal nitric oxide synthase (nNOS) and vasoactive
intestinal polypeptide (VIP), but not choline acetyltransferase
(ChAT), substance P and iNOS (data not shown) (Fig. 4B and
C). It indicated that Prok-1 is able to promote the differentiation
of NCCs, at least, to neural/glial lineages.
Prokineticins have been implicated in the mediation of
hematopoietic cell mobilization [27]. Therefore, the effect ofs expression of neuronal and glial markers in NCCs. Representative pictures for
sence of vehicle or Prok-1 for 48 h. Then, the cells were cytospun onto the coated
ronal- (Tuj1, TH and neurofilament) and glial- (GFAP and S100) lineages. In the
r glial markers. On the other hand, Tuj1+, TH+, Neurofilament+. GFAP+ or S100+
ing neuronal and glial markers in Prok-1 treated culture were summarized in the
ounted in two independent experiments. Pictures were taken at 400×. Bars 50 μm
Cs were cultured in the presence of vehicle or Prok-1 for 6 consecutive days.
vasoactive intestinal polypeptide, Choline acetyltransferase, nitric oxide synthase
the internal control. (D) E11.5 mid- guts were isolated from ICRmice and placed
esence of Prok-1, GDNF or in combination for 48 h. Tuj1+ NCCs migrated onto
r 200 μm.
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explant culture in accordance with a previously described
protocol [12]. E11.5 midguts were isolated from ICR mice and
placed on the filter membrane. The explants were then cultured
in the absence (vehicle) or presence of Prok-1, GDNF or in
combination for 48 h. Tuj1+ NCCs migrated onto the membrane
were then visualized by immunostaining with anti-Tuj1
antibody. Unlike GDNF, Prok-1 was unable to induce the
migration of NCCs of E11.5 gut in the ex vivo culture (Fig. 4D).
3.5. Prok-1 mediated proliferation depends on both MAPK and
Akt phosphorylation
Recently, the signal transduction events initiated by Prok-1
in hematopoietic stem cells were reported [27]. Given thatFig. 5. Proliferative effect of Prok-1 is mediated by PI-3-K and MAPK
pathways. (A) Cell proliferation ELISA assay. NCCs were treated with vehicle,
Prok-1 in the presence or absence of PI-3-K inhibitor (LY294002) and MAPK
inhibitor (PD98059) for 24 h. Proliferating cells were incorporated with BrdU
and the relative proliferation rate was measured by ELISA using anti-BrdU
antibody. The value reported in bar charts represent the mean±SEM of 3
independent assays, each in triplicate. Data were analyzed by one-way ANOVA
followed by the Tukey posttest. A p value less than 0.05 indicates statistical
significance. (B, C) Western blot analysis. NCCs were cultured in the presence
of vehicle, Prok-1, Prok-1+MAPK inhibitor (PD98059) and Prok-1+PI-3-K
inhibitor (LY294002) for 20 min. Cell lysates were obtained and western blot
was performed. Prok-1 significantly increased the phosphorylation of both
MAPK (B) and Akt (C) compared to vehicle. Prok-1-induced NCC Proliferation
(A) and substrate phosphorylation (B, C) was inhibited by MAPK and PI-3-K
inhibitors.Prok-1 promotes mitogenesis and differentiation of NCCs,
MAPK and Akt activation were evaluated by using MAPK and
Akt inhibitors (PD98059 and LY294002) as well as phosphor-
ylation-specific antibodies. Consistently, by ELISA assay,
Prok-1 enhanced the proliferation of NCCs by 1.2±0.03 fold
relative to untreated control. In the presence of MAPK inhibitor
(PD98059), Prok-1 induced proliferation was completely
abolished (1.0±0.05 fold relative to the vehicle treated control,
p<0.05). Further, Akt inhibitor (LY294002) ablates not only
the Prok-1 induced, but also the intrinsic proliferation of NCCs
(0.76±0.05 fold) (Fig. 5A). Subsequent Western blot analysis
of phosphorylated MAPK, p44 and p42, or phosphorylated Akt
(a PI-3-K target) further confirmed the activations of the
MAPK and Akt pathways by Prok-1 in NCCs. Comparable to
other cells, Prok-1 markedly induced phosphorylation of
MAPK within 20 min of stimulation. It is also noteworthy
that unlike in other cells, Prok-1 mainly increased phosphory-
lated p44, but not p42 in NCCs (Fig. 5B). The activation was
specific and inhibited by MAPK inhibitor (PD98059).
Similarly, Akt phosphorylation was markedly increased above
control culture at 20 min of incubation with Prok-1 and was
abolished by Akt inhibitor (LY294002) (Fig. 5C).
4. Discussion
The hypothesis was tested that Prok-1 signaling is not limited
to mediating the muscle contraction of gastrointestinal tract in
mature gut but also regulates the development of the ENS from
crest-derived emigrants. Transcripts encoding Prok-1, and its
receptor PK-R1 were detected in the bowel as early as at E11.5
which is a critical time point for colonization. Both Prok-1 and
PK-R1 expressions were persistent throughout development.
However, NCCs express only PK-R1, and not the closely related
receptor PK-R2. Together with the subsequent PK-R1 knock
down experiment further confirmed that Prok-1 exhibits its
functions only via PK-R1 during ENS development. As a matter
of fact, the distinct expression patterns of Prokineticin receptors
were observed in various tissues. In the adrenal gland, only PK-
R1was detected [33]. In the ovary, follicular cells predominantly
express PK-R1, whereas corpus luteum-derived cells express
high levels of both PK-R1 and PK-R2 [21]. Similarly, these two
receptors also co-exist in the endometrium, but at different
expression level [19,24]. Therefore, it is believed that prokine-
ticins may have different angiogenic as well as non-angiogenic
functions in different tissues via acting on either PK-R1 or PK-
R2. Recently, PK-R1−/− and PK-R2−/− mice were generated
[34]. PK-R2−/− mice exhibited hypoplasia of olfactory bulb and
abnormal reproductive system, whereas PK-R1−/− showed no
phenotypic defect in these two systems. It suggests that these
two receptors are playing differential roles in various systems.
PK-R1−/− mice are vital, indicating that a functional enteric
nervous system can develop without PK-R1 expression.
While subtle morphological or physiological deficits may
exist, but not as severe as the aganglionosis associated with
Ret−/− /Gdnf −/−. PK-R1−/− mice would be a good model for
the future study on the in vivo function of Prok-1 on ENS
development.
544 E.S.W. Ngan et al. / Biochimica et Biophysica Acta 1773 (2007) 536–545In this report, we elucidated function of Prok-1 in an in vitro
NCC culture system, which was established using E11.5
embryonic guts. Immunohistochemical studies demonstrated
that, if not all, at least a population of NCCs at E11.5 embryonic
guts have already committed to neural fate and expressed
neuronal marker, Tuj1 (Fig. 1). After the NCCs were isolated
and grew in the NCC specific growth medium, the majority of
NCCs were shown to be “primitive” and did not express Tuj1
(Fig. 4). This is perhaps because the NCC growth medium only
favors the growth of “primitive” cells and the committed or
differentiated cells were removed after multiple re-plating.
Alternatively, we cannot exclude the possibility that those
committed cells are able to dedifferentiate. More importantly,
the “primitive” (p75NTR+/RET+/Tuj1+) NCCs express func-
tional receptors for Prok-1 and are multipotent. In sum, this
provided a firm foundation for us to assess the role of Prok-1 on
NCC proliferation and differentiation.
Using our in vitro NCC culture system, we showed that
Prok-1, like GDNF, is able to induce the proliferation and
differentiation of NCCs. Downstream, both GDNF and Prok-1
share common elements, most prominently the MAPK and
PI3K pathways, which provide multiple points of intersections
between these two factors. As reported recently by Srinivasan
et. al., the PI3K/Akt/FOXO signaling pathway (but not
MAPK, pathway) is pivotal for GDNF stimulated ENS
precursor survival and neurite extension [35]. In our study, we
found that both Akt and MAPK signalings are essential for the
Prok-1 induced proliferation of NCCs, and Akt and MAPK
inhibitors completely abolish Prok-1 induced proliferation.
Further, in some aspects, GDNF and Prok-1 also work quite
differently. GDNF is a potent chemoattractant for NCCs [36],
which mediates the rostro-caudal migration of NCCs for gut
colonization. However, Prok-1 was not able to induce migration
of NCCs in the ex vivo gut explant cultures. Taken together,
GDNF and Prok-1 may share some but not all the downstream
elements. Importantly, they exhibit similar biological functions.
The functional redundancy of Prok-1 and GNDF may support
the idea that Prok-1 provides a compensatory pathway to ensure
the proper development of ENS. To demonstrate this idea, a
double mutant (c-Ret+/− and PK-R1−/−) mice may be required
for the future studies.
Recently, Micci et al. successfully used neural stem cell
isolated from the central nervous system (CNS) to perform
transplantation in the stomach and rescued gastric function in
neuronal nitric oxide synthase-deficient mice [37]. However,
neurons of the CNS, although resembling enteric neurons in
many ways, are derived from a distinct pool of precursor cells in
early embryonic life. Enteric neurons are the end product of
migratory stem cells originating in the neural crest. Therefore,
based on the assumption that cells are more “naturally poised”
to generate a particular tissue and require little or no
manipulation either in vivo or in vitro, enteric neural crest
cells are more obvious candidates for use in the cell replacement
therapy for neuroenteric disorders. It is noteworthy that
Prokineticins is a universal survival factor/mitogen and
subserves similar functions in both CNS and peripheral nervous
system (PNS). In CNS, mainly Prok-2, mediates neuralprotection or survival [16,30] and Prok-1 is a mediator for the
proliferation of neuronal precursor cells in ENS. The data from
this study, therefore, may not only enhance our understanding of
the biology of ENS development, but also the future
optimization of NCC or neural stem cell culture condition for
the therapeutic use.
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